ETI Karle Clinical, based in India, will conduct Oramed Pharmaceuticals Phase IIb trials on its oral insulin capsules in diabetic type 2 patients.


It is anticipated that the Phase IIb study will enroll 60 subjects and begin in the first quarter of 2009.

BiopharmaceuticalsClinical drug developmentDiabetesDrug development (Research and development)DrugsEndocrine diseasesMedicine, Diagnosis, and TherapeuticsMetabolic disordersPharmacologyPhase II clinical trials (Drug development)Research and developmentSystemic conditionsOramed Pharmaceuticals
Next articleUMMZ Periodical Cicada Page
Also of Interest
Novel Approach Restores Brain Function after Stroke-Like Injury in Mice
StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
Genomes Reveal the Encounter between Neanderthals and Sapiens
Accelerating Drug Development Using Medical Imaging AI
Using Single Cell Spatial Profiling to Study Therapeutic Response in Neurological Disease and Injury
Commensal E. coli in Gut Readily Displaced by Drug-Resistant E. coli
Related Media
Nobel Winner Katalin Karikó Shared mRNA Vaccine Story with GEN, Mid-Pandemic
Bioprocessing in Beantown: GEN Reports Live from Day 2 at BPI
Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning
Excitement in Oakland: A Report from SynBioBeta
Carl Icahn States His Case for Change at Illumina on “Close to the Edge”
Celebrating DNA: Matthew Cobb’s Reflections on the Double Helix